Hormone therapy in Europe offers potential benefits like improved bone health and reduced Alzheimer's risk, but further research is needed for long-term safety and effectiveness.
FREMONT, CA: As Europe's demographic landscape undergoes rapid ageing, the imperative to prioritise healthy ageing initiatives has gained significant importance. Within this context, hormone therapy (HT) has emerged as a promising intervention to address the physiological decline in hormone levels associated with ageing. This therapy presents a spectrum of potential benefits, contributing to the ongoing discourse on enhancing the quality of life among European ageing populations.
HT is designed to address declining hormone levels and alleviate associated negative impacts. It offers a range of potential benefits, including enhanced bone health by reducing the risk of osteoporosis in women through estrogen therapy. Moreover, HT can effectively alleviate menopausal symptoms such as hot flashes, night sweats, and vaginal dryness, thereby enhancing the quality of life for women experiencing these challenges. Additionally, there is emerging evidence suggesting a positive impact of HT on cognitive function, potentially lowering the risk of Alzheimer's disease and dementia. However, further research is warranted in this area. Testosterone therapy has shown promise in increasing muscle mass and strength in men, consequently improving physical function. Furthermore, both estrogen and testosterone therapy can positively influence sexual health, potentially enhancing sexual function in both men and women. These potential benefits underscore the significance of hormone therapy in addressing various health concerns associated with hormonal imbalances.
The utilisation of HT within Europe has exhibited variability over time, notably influenced by safety apprehensions raised in extensive studies dating back to the early 2000s. Nonetheless, recent advancements in research coupled with a refined comprehension of HT have sparked a renewed interest in its application. European guidelines underscore the significance of a tailored approach to HT, emphasising individualised care that accounts for age, overall health, and the prospective risks and benefits specific to each patient. Additionally, there is a burgeoning interest in bioidentical hormones, which mirror the molecular structure of naturally occurring hormones in the body. Nevertheless, further investigation is imperative to ascertain their prolonged safety and effectiveness in clinical practice.
